Enobosarm Has Antitumor Activity in ER-Positive, HER2-Negative Advanced Breast Cancer
By Elana Gotkine HealthDay Reporter
TUESDAY, Feb. 27, 2024 -- The oral selective androgen receptor modulator enobosarm has antitumor activity and can yield clinical benefit in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, according to a study published online Feb. 8 in The Lancet Oncology.
Carlo Palmieri, M.B.B.S., Ph.D., from The Clatterbridge Cancer Centre NHS Foundation Trust in Liverpool, England, and colleagues examined the activity and safety of enobosarm in women with ER-positive, HER2-negative, and androgen receptor (AR)-positive disease. Postmenopausal women with previously treated ER-positive, HER2-negative, locally advanced or metastatic breast cancer were enrolled in a randomized trial conducted at 35 centers in nine countries. Participants were randomly allocated to receive 9 mg or 18 mg of oral enobosarm daily (72 and 64 patients, respectively). The evaluable population included 50 and 52 patients, respectively).
Patients were followed for a median of 7.5 months. The researchers found that 32 and 29 percent of the patients in the 9-mg and 18-mg groups, respectively, had clinical benefit at 24 weeks. Overall, 8 and 16 percent of those receiving 9 mg and 18 mg, respectively, had grade 3 or grade 4 drug-related adverse events, most frequently increased hepatic transaminases, hypercalcemia, and fatigue.
"The data from this study provide proof-of-concept for the activity and safety of a novel selective AR modulator, enobosarm, in AR-positive, ER-positive, and HER2-negative metastatic breast cancer, thus supporting the premise that activating AR can exert antitumor effects," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Veru, which manufactures enobosarm; the study was funded by GTx, which originally developed enobosarm.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
Some Women in Their 40s Prefer to Delay Breast Cancer Screening
MONDAY, July 15, 2024 -- A considerable proportion of women aged 39 to 49 years prefer to delay breast cancer screening, especially after a decision aid (DA) intervention...
NCCN: Cancer Drug Shortages Remain a Challenge for Clinicians
FRIDAY, June 28, 2024 -- Almost 90 percent of medical centers report cancer drug shortages, which often impact clinical trials, according to the results of a National...
Acupuncture Reduces Endocrine Symptoms, Hot Flashes in Breast Cancer
MONDAY, June 24, 2024 -- A 10-week acupuncture intervention significant reduces endocrine symptoms and hot flashes among women with breast cancer receiving endocrine therapy (ET)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.